Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.50 |
| ▸ | RXRB | P28702 | 4/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421692 | 0.98 | RXRA (0.49) | RXRARXRBRXRGNOTUMSRD5A2 | |
| SCHEMBL3072277 | 0.86 | NOTUM (0.45) | RXRARXRBRXRGNOTUMSRD5A2 | |
| SCHEMBL166878 | 0.85 | RXRB (0.59) | RXRARXRBRXRGSRD5A2SMN1; SMN2 | |
| SCHEMBL501957 | 0.85 | RXRB (0.64) | RXRARXRBRXRGSRD5A2SMN1; SMN2 | |
| SCHEMBL23411618 | 0.85 | NOTUM (0.51) | RXRARXRBRXRGNOTUMSRD5A2 | |
| SCHEMBL29728800 | 0.85 | NOTUM (0.51) | RXRARXRBRXRGNOTUMSRD5A2 | |
| SCHEMBL23411745 | 0.85 | NOTUM (0.51) | RXRARXRBRXRGNOTUMSRD5A2 | |
| SCHEMBL29728806 | 0.85 | NOTUM (0.51) | RXRARXRBRXRGNOTUMSRD5A2 | |
| SCHEMBL12187515 | 0.84 | NOTUM (0.46) | RXRARXRBRXRGNOTUMSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11879619 | 0.83 | RXRB (0.57) | RXRARXRBRXRGSRD5A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023061263-A1 | SHP2 INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 北京泰德制药股份有限公司 | 2023-04-20 | — | — | WO | disclosed |
| US-11040028-B2 | Penicinotam derivative, preparation method and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2021-06-22 | — | — | US | disclosed |
| US-10993938-B2 | Lactam compound, preparation method and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2021-05-04 | — | — | US | disclosed |
| US-20210008045-A1 | PANICINOTAM DERIVATIVE, PREPARATION METHOD AND USE THEREOF | OCEAN UNIVERSITY OF CHINA (CN) | 2021-01-14 | — | — | US | disclosed |
| EP-3394059-B1 | 1-(3-TERT-BUTYL-PHENYL)-3-(4-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YLOXY)-1,2,3,4-TETRAHYDRO- NAPHTHALEN-1-YL)-UREA DERIVATIVES AND THEIR USE AS P38 MAPK INHIBITORS | CHIESI FARM SPA (IT) | 2020-11-25 | — | — | EP | disclosed |
| US-20200030312-A1 | Lactam Compound, Preparation Method and Use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2020-01-30 | — | — | US | disclosed |
| EP-3394059-A1 | 1-(3-TERT-BUTYL-PHENYL)-3-(4-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YLOXY)-1,2,3,4-TETRAHYDRO- NAPHTHALEN-1-YL)-UREA DERIVATIVES AND THEIR USE AS P38 MAPK INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2018-10-31 | — | — | EP | disclosed |
| US-10100050-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-10-16 | — | — | US | disclosed |
| WO-2017108737-A1 | 1-(3-TERT-BUTYL-PHENYL)-3-(4-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YLOXY)-1,2,3,4-TETRAHYDRO- NAPHTHALEN-1-YL)-UREA DERIVATIVES AND THEIR USE AS P38 MAPK INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-06-29 | — | — | WO | disclosed |
| US-20170183345-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-06-29 | — | — | US | disclosed |
| US-20120010203-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2012-01-12 | — | — | US | disclosed |
| EP-2240487-B1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI SA (FR) | 2011-12-14 | — | — | EP | disclosed |
| US-8076336-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI-AVENTIS (FR) | 2011-12-13 | — | — | US | disclosed |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| EP-2240487-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| EP-2240486-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009097971-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097970-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| US-20010016657-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. | 2001-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | RXRA 3073/4885RXRB 3217/4885RXRG 3121/4885 |
| US-20200030312-A1 | Lactam Compound, Preparation Method and Use thereof | FURIN, PEPD, PIN1 | RXRA 4651/4885RXRB 4694/4885RXRG 4551/4885 |
| US-20010016657-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | INA, GRIN2C, GRIN2A | RXRA 1791/4885RXRB 1748/4885RXRG 1862/4885 |
| US-10993938-B2 | Lactam compound, preparation method and use thereof | FURIN, PEPD, PIN1 | RXRA 4651/4885RXRB 4694/4885RXRG 4551/4885 |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | RXRA 2080/4885RXRB 2530/4885RXRG 2237/4885 |
| US-10100050-B2 | Kinase inhibitors | MAPK1, MAP3K1, MAP3K6 | RXRA 1744/4885RXRB 1459/4885RXRG 1620/4885 |
| US-20120010203-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | RXRA 3073/4885RXRB 3217/4885RXRG 3121/4885 |
| US-20170183345-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K6 | RXRA 1744/4885RXRB 1459/4885RXRG 1620/4885 |
| US-11040028-B2 | Penicinotam derivative, preparation method and use thereof | TPMT, MAPT, TLR4 | RXRA 2498/4885RXRB 2516/4885RXRG 2879/4885 |
| US-20210008045-A1 | PANICINOTAM DERIVATIVE, PREPARATION METHOD AND USE THEREOF | TPMT, PBRM1, PGM2 | RXRA 1568/4885RXRB 1630/4885RXRG 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.